(19)
(11)EP 2 644 194 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
01.01.2014 Bulletin 2014/01

(43)Date of publication A2:
02.10.2013 Bulletin 2013/40

(21)Application number: 13158350.2

(22)Date of filing:  10.03.2009
(51)International Patent Classification (IPC): 
A61K 31/337(2006.01)
A61K 39/395(2006.01)
A61P 35/00(2006.01)
(84)Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA RS

(30)Priority: 18.03.2008 US 37410 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
09721522.2 / 2254571

(71)Applicant: Genentech, Inc.
South San Francisco, CA 94080 (US)

(72)Inventors:
  • Berry, Leanne
    South San Francisco, CA California 94080 (US)
  • Phillips, Gail, Lewis
    San Carlos, CA California 94070 (US)
  • Sliwkowski, Mark, X.
    San Carlos, CA California 94070 (US)

(74)Representative: Kiddle, Simon John 
Mewburn Ellis LLP 33 Gutter Lane
London EC2V 8AS
London EC2V 8AS (GB)

  


(54)Combinations of an anti-HER2 antibody-drug conjugate and docetaxel


(57) Combinations of the antibody-drug conjugate trastuzumab-MCC-DM and docetaxel.





Search report


















Search report